Cargando…

Targeting Mutant KRAS in Pancreatic Cancer: Futile or Promising?

Pancreatic ductal adenocarcinoma (PDAC) is one of the most fatal cancers with a dismal prognosis for the patient. This is due to limited diagnostic options for the early detection of the disease as well as its rather aggressive nature. Despite major advances in oncologic research in general, the tre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nollmann, Friederike Inga, Ruess, Dietrich Alexander
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7459579/ https://www.ncbi.nlm.nih.gov/pubmed/32796566 http://dx.doi.org/10.3390/biomedicines8080281

Ejemplares similares

Targeting KRAS in Cancer: Promising Therapeutic Strategies
por: Mustachio, Lisa Maria, et al.
Publicado: (2021)

Targeting KRAS in Pancreatic Cancer
por: Cowzer, Darren, et al.
Publicado: (2022)

KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment
por: Zeitouni, Daniel, et al.
Publicado: (2016)

Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC
por: Liu, Weiran, et al.
Publicado: (2016)

Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
por: Adachi, Yuta, et al.
Publicado: (2021)

Targeting KRAS mutant lung cancer: light at the end of the tunnel
por: Drosten, Matthias, et al.
Publicado: (2022)

Targeting KRAS mutant cancers: from druggable therapy to drug resistance
por: Zhu, Chunxiao, et al.
Publicado: (2022)

Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pancreatic cancer
por: Frank, Katrin J., et al.
Publicado: (2022)

Photorespiration: The Futile Cycle?
por: Shi, Xiaoxiao, et al.
Publicado: (2021)

A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
por: Pang, Xiufeng, et al.
Publicado: (2016)

KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup
por: Xie, Mingying, et al.
Publicado: (2021)

KRAS mutant lung cancer: progress thus far on an elusive therapeutic target
por: Bhattacharya, Saveri, et al.
Publicado: (2015)

Targeting the Tumor Microenvironment: An Unexplored Strategy for Mutant KRAS Tumors
por: Dias Carvalho, Patrícia, et al.
Publicado: (2019)

The Futility of Futility Analyses in Adjuvant Trials in Hormone Receptor–Positive Breast Cancer
por: Lohmann, Ana Elisa, et al.
Publicado: (2022)

Exploiting macropinocytosis for drug delivery into KRAS mutant cancer
por: Liu, Huiqin, et al.
Publicado: (2022)

Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future
por: Uras, Iris Z., et al.
Publicado: (2020)

KRAS-Mutant Lung Cancer: Targeting Molecular and Immunologic Pathways, Therapeutic Advantages and Restrictions
por: Karimi, Nastaran, et al.
Publicado: (2023)

The Futility of Flogging
Publicado: (1921)

Resistance is futile
por: Semler, Bert L
Publicado: (2005)

Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma
por: Neel, Dana S., et al.
Publicado: (2017)

A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS
por: Bery, Nicolas, et al.
Publicado: (2020)

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2019)

Thioredoxin system-mediated regulation of mutant Kras associated pancreatic neoplasia and cancer
por: Schultz, Michelle A., et al.
Publicado: (2017)

NURSES’ PERCEPTIONS OF FUTILE MEDICAL CARE
por: Rostami, Somayeh, et al.
Publicado: (2016)

Metabolic profiling of induced acute pancreatitis and pancreatic cancer progression in a mutant Kras mouse model
por: Carneiro, Tatiana J., et al.
Publicado: (2022)

Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas
por: Baldelli, Elisa, et al.
Publicado: (2021)

Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2020)

Addressing Futility: A Practical Approach
por: Kopar, Piroska K., et al.
Publicado: (2022)

KRAS mutant allele-specific expression knockdown in pancreatic cancer model with systemically delivered bi-shRNA KRAS lipoplex
por: Rao, Donald D., et al.
Publicado: (2018)

The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancer
por: Diehl, J. Nathaniel, et al.
Publicado: (2021)

Targeting KRAS in Pancreatic Ductal Adenocarcinoma: The Long Road to Cure
por: de Jesus, Victor Hugo Fonseca, et al.
Publicado: (2023)

Enhancing an Oxidative “Trojan Horse” Action of Vitamin C with Arsenic Trioxide for Effective Suppression of KRAS-Mutant Cancers: A Promising Path at the Bedside
por: Burska, Agata N., et al.
Publicado: (2022)

Synergistic blocking of RAS downstream signaling and epigenetic pathway in KRAS mutant pancreatic cancer
por: Zhang, Xiaofei, et al.
Publicado: (2022)

Targeting Myc-driven stress vulnerability in mutant KRAS colorectal cancer
por: Ruan, Hang, et al.
Publicado: (2022)

Targeting the DNA replication stress phenotype of KRAS mutant cancer cells
por: Al Zubaidi, Tara, et al.
Publicado: (2021)

Laying Futility to Rest
por: Nair-Collins, Michael
Publicado: (2015)

Predicting Resistance Is (Not) Futile
por: Brankin, Alice E., et al.
Publicado: (2019)

NF-κB/Rel Transcription Factors in Pancreatic Cancer: Focusing on RelA, c-Rel, and RelB
por: Kabacaoglu, Derya, et al.
Publicado: (2019)

The Diagnostic Accuracy of Mutant KRAS Detection from Pancreatic Secretions for the Diagnosis of Pancreatic Cancer: A Meta-Analysis
por: Patel, Nikhil, et al.
Publicado: (2020)

Current therapy of KRAS-mutant lung cancer
por: Ghimessy, Aron, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_njbqtiqh46rh5prg0babtue0gr